Axid Related Published Studies
Well-designed clinical trials related to Axid (Nizatidine)
Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily. [2010.04]
Multicenter, double-blind, placebo-controlled crossover study to assess the acute
prokinetic efficacy of nizatidine-controlled release (150 and 300 mg) in patients
with gastroesophageal reflux disease. [2010]
Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis
of two previously published studies comparing pantoprazole 20 mg once daily with
nizatidine or ranitidine 150 mg twice daily. [2010]
Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine. [2006.12]
Pharmacokinetics of ranitidine and nizatidine in very elderly patients. [2005.05]
Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children. [2005.04]
Bioequivalence of two oral formulations of nizatidine capsules in healthy male volunteers. [2005.04]
Comparative study of nizatidine and famotidine for maintenance therapy of erosive esophagitis. [2005.02]
Developmental pharmacokinetics and pharmacodynamics of nizatidine. [2004.04]
Nizatidine for the treatment of patients with quetiapine-induced weight gain. [2004.01]
Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. [2003.08]
Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine. [2003.08]
Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. [2003.03]
Pharmacokinetics and pharmacodynamics of a novel nizatidine controlled-release formulation in healthy subjects. [2003.01]
Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study. [2002.12]
Lack of effect of nizatidine-induced elevation of gastric pH on the oral bioavailability of dapsone in healthy volunteers. [2002.11]
Effect of preoperative oral use of erythromycin and nizatidine on gastric pH and volume. [2002.08]
H2 histamine receptor blockade in the treatment of Alzheimer disease: a randomized, double-blind, placebo-controlled trial of nizatidine. [2002.01]
Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. [2001.10]
Effectiveness and safety of nizatidine, 75 mg, for the relief of episodic heartburn. [2001.10]
Nizatidine enhances the gastrocolonic response and the colonic peristaltic reflex in humans. [2001.10]
The effect of previous administration of nizatidine on the neuromuscular effects of vecuronium and the effect of nizatidine on gastric secretion. [2000.02]
Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection. [1998.06]
Placebo-controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia. [1998.03]
A double-blind, placebo-controlled study of the effectiveness and safety of nizatidine in the prevention of postprandial heartburn. [1997.07.28]
Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. [1997.07]
Twice daily nizatidine or ranitidine is superior to once daily dosing in elevating 24 h intragastric pH in patients with duodenal ulcer disease. [1996.12]
Diurnal variation in the pharmacokinetics of nizatidine in healthy volunteers and in patients with peptic ulcer disease. [1995.11]
Effect of nizatidine and ranitidine on 24 hour intragastric pH, pepsin, prostaglandin E2 and serum gastrin concentrations in healthy volunteers. [1995.09]
Gastric fluid volume and pH after nizatidine in adults undergoing elective surgery: influence of timing and dose. [1995.08]
A single standard nocturnal dose of nizatidine enhances the healing of active duodenal ulcers among Chinese. [1995.03]
Effects of oral nizatidine on preoperative gastric fluid pH and volume in children. [1994.11]
Nizatidine versus placebo in gastro-oesophageal reflux disease: a 12-week, multicentre, randomised, double-blind study. [1994.11]
The effect of nizatidine on duodenal ulcer healing and on mucosal inflammatory mediators. [1994.10]
Risk factors of relapse in gastric ulcer: a one-year, double-blind, comparative study of nizatidine versus placebo. [1994.01]
Effect of nizatidine versus ranitidine on gastric intraluminal prostaglandin release in duodenal ulcer patients. [1994]
Nizatidine as maintenance treatment of duodenal ulcer. Clinical results. [1994]
A quality of life study in five hundred and eighty-one duodenal ulcer patients. Maintenance versus intermittent treatment with nizatidine. [1994]
Continuous infusions of nizatidine are safe and effective in the treatment of intensive care unit patients at risk for stress gastritis. The Nizatidine Intensive Care Unit Study Group. [1994]
Nizatidine in therapy and prevention of non-steroidal anti-inflammatory drug-induced gastroduodenal ulcer in rheumatic patients. [1994]
Histologic patterns of omeprazole and nizatidine-healed duodenal ulcers:accuracy of endoscopic diagnosis. [1994]
Peptic ulcer in the elderly--a double-blind, short-term study comparing nizatidine 300 mg with ranitidine 300 mg. GISU (Interdisciplinary Ulcer Study Group). [1993.12]
Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs. [1993.11.08]
[Nizatidine in therapy and prevention of non-steroidal anti-rheumatic drug-induced ulcers in rheumatic patients] [1993.06]
Dose-dependent heart rate reducing effect of nizatidine, a histamine H2-receptor antagonist. [1993.05]
Early evening nizatidine intake with a meal optimizes the antisecretory effect. [1993.02]
Twenty-four-hour control of gastric acidity by twice-daily doses of placebo, nizatidine 150 mg, nizatidine 300 mg, and ranitidine 300 mg. [1993.01]
Changes in the effects of nizatidine and famotidine on cardiac performance after pretreatment with ranitidine. [1993]
The effect of a single oral morning dose of nizatidine and ranitidine on intragastric pH under basal conditions and after pentagastrin stimulation. [1992.11]
Nizatidine versus placebo in active benign gastric ulcer disease: an eight-week, multicenter, randomized, double-blind comparison. The Nizatidine Benign Gastric Ulcer Disease Study Group. [1992.09]
Treatment of erosive reflux oesophagitis: a double-blind multicentre trial with nizatidine 300 mg b.i.d. versus placebo. [1992.07]
Nizatidine versus placebo in gastroesophageal reflux disease. A six-week, multicenter, randomized, double-blind comparison. Nizatidine Gastroesophageal Reflux Disease Study Group. [1992.06]
[Modern trends in the treatment of ulcer disease (clinical study of nizatidine "Galitidine")] [1992]
Nizatidine versus placebo in gastroesophageal reflux disease: a 12-week, multicenter, randomized, double-blind study. [1991.12]
Comparison of the effects of oral nizatidine and ranitidine on gastric volume and pH in patients undergoing gynaecological laparoscopy. [1991.10]
Rebound hypersecretion after H2-antagonist withdrawal--a comparative study with nizatidine, ranitidine and famotidine. [1991.08]
Negative chronotropic effects of nizatidine. [1991.06]
A comparison of nizatidine and ranitidine in the maintenance treatment of duodenal ulcer. A randomized, double blind, multicentre, 2-year study. [1991.06]
Comparison of 150 mg nizatidine BID or 300 mg at bedtime, and 150 mg ranitidine BID in the treatment of gastric ulcer--an 8-week randomized, double-blind multicentre study. [1990.12]
Nizatidine versus ranitidine in the treatment of peptic ulcer disease: report on the Dutch investigation as part of a European multicentre trial. [1990.08]
A comparison of two doses of nizatidine versus placebo in the treatment of reflux oesophagitis. [1990.04]
[Effective prevention of piroxicam-induced lesions of the gastric mucosa with nizatidine] [1990.02]
Weakening effect of famotidine but not of nizatidine on the mucus-bicarbonate barrier of the human stomach. [1990]
Nizatidine suppression of basal gastric acid output: a comparison of two intravenous dosage regimens. [1989.10]
Healing and recurrence of active duodenal ulcer with nizatidine. [1989.09]
Comparison of nizatidine and cimetidine as once-nightly treatment of acute duodenal ulcer. Nizatidine Multicenter Duodenal Ulcer Study Group. [1989.07]
Twenty four hour intragastric acidity and plasma gastrin concentration in healthy volunteers taking nizatidine 150 mg, nizatidine 300 mg, ranitidine 300 mg, or placebo at 21:00 h. [1988.10]
Pharmacokinetics and pharmacodynamics of oral nizatidine. [1988.01]
Do nizatidine and cimetidine interact with ibuprofen? [1988]
Nizatidine in the short-term treatment of duodenal ulcer--an Italian Multicenter Study. [1987.12]
Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam. [1987.03]
Nizatidine versus ranitidine in the prevention of duodenal ulcer relapse. Six-month interim results of a European multicentre study. [1987]
Nizatidine as maintenance therapy of duodenal ulcer disease in remission. [1987]
Nizatidine versus ranitidine in gastric ulcer disease. A European multicentre trial. [1987]
300 mg nizatidine at night versus 300 mg ranitidine at night in patients with duodenal ulcer. A multicentre trial in Europe. [1987]
The 24-hour acid suppression profile of nizatidine. [1987]
The effect of an oral evening dose of nizatidine on nocturnal and peptone-stimulated gastric acid and gastrin secretion. [1987]
Well-designed clinical trials possibly related to Axid (Nizatidine)
Effectiveness of medications used to attenuate antipsychotic-related weight gain
and metabolic abnormalities: a systematic review and meta-analysis. [2010]
Little necessity of acid inhibition against proton pump inhibitor rebound effects and prior helicobacter pylori eradication therapy in gastric ulcer patients: a randomized prospective study. [2009.05]
Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis. [2009.03.28]
Use of histamine2-antagonists for the treatment of verruca vulgaris. [2007.07]
Use of Histamine2-Antagonists for the Treatment of Verruca Vulgaris (July/August). [2007.05.29]
Teprenone, but not H2-receptor blocker or sucralfate, suppresses corpus Helicobacter pylori colonization and gastritis in humans: teprenone inhibition of H. pylori-induced interleukin-8 in MKN28 gastric epithelial cell lines. [2004.04]
Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. [2003.05.15]
Validation of the GSFQ, a self-administered symptom frequency questionnaire for patients with gastroesophageal reflux disease. [2003.05]
Cimetidine reduces impairment of cellular immunity after transcatheter arterial embolization in patients with hepatocellular carcinoma. [2003.03]
Eradication of Helicobacter pylori infection in patients with duodenal ulcer and non-ulcer dyspepsia and analysis of one-year reinfection rates. [2001.06]
Obstructive sleep apnea and gastroesophageal reflux. [2000.03.06]
The therapeutic effect of proton pump inhibitors on Helicobacter pylori-positive gastric ulcers. [1999.07]
New one-week, low-dose triple therapy for the treatment of duodenal ulcer with Helicobacter pylori infection. [1998.08]
Correlation of the end-tidal PCO2 during laparoscopic surgery with the pH of the gastric juice. [1998.04]
Clarithromycin in the combination therapy for the eradication of Helicobacter pylori in peptic ulcer disease. [1997.03]
Triple therapy for the eradication of Helicobacter pylori and reduction of duodenal ulcer relapse: comparison of 1 week and 2 week regimens and recrudescence rates over 12 months. [1995.05]
Gastric ulcer in the elderly. [1994.01]
Histamine-2 receptor antagonists do not alter serum ethanol levels in fed, nonalcoholic men. [1993.04.01]
Effects of H2 blockers and omeprazole on peptic secretion: a prospective, randomized study in duodenal ulcer subjects. [1993.03]
The consequences of H2 receptor antagonist--piroxicam coadministration in patients with joint disorders. [1993]
Role of H2-receptor antagonists in the treatment of duodenitis. [1992.07]
The medical management of reflux esophagitis. Role of antacids and acid inhibition. [1990.09]
Continuous intragastric pH monitoring: a real progress in the assessment of antisecretory drugs. [1990]
Low bedtime doses of H2-receptor antagonists for acute treatment of duodenal ulcer. [1989.07]
|